Drug release and swelling kinetics of directly compressed glipizide sustained-release matrices: establishment of level A IVIVC.
The purpose of this study was to examine a level A in vitro-in vivo correlation (IVIVC) for glipizide hydrophilic sustained-release matrices, with an acceptable internal predictability, in the presence of a range of formulation/manufacturing changes. The effect of polymeric blends of ethylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, xanthan gum, guar gum, Starch 1500, and lactose on in vitro release profiles was studied and fitted to various release kinetics models. Water uptake kinetics with scanning electron microscopy (SEM) was carried out to support the drug release mechanism. An IVIVC was established by comparing the pharmacokinetic parameters of optimized (M-24) and marketed (Glytop-2.5 SR) formulations after single oral dose studies on white albino rabbits. The matrix M-19 (xanthan:MCC PH301 at 70:40) and M-24 (xanthan:HPMC K4M:Starch 1500 at 70:25:15) showed the glipizide release within the predetermined constraints at all time points with Korsmeyer-Peppas' and zero-order release mechanism, respectively. Kopcha model revealed that the xanthan gum is the major excipient responsible for the diffusional release profile and was further supported by SEM and swelling studies. A significant level A IVIVC with acceptable limits of prediction errors (below 15%) enables the prediction of in vivo performance from their in vitro release profile. It was concluded that proper selection of rate-controlling polymers with release rate modifier excipients will determine overall release profile, duration and mechanism from directly compressed matrices.
Sankalia
Jolly M
JM
Centre of Relevance and Excellence in Novel Drug Delivery Systems, Pharmacy Department, The M. S. University of Baroda, G. H. Patel Building, Donor's Plaza, Vadodara, Gujarat 390002, India. jollymayur@hotmail.com
Sankalia
Mayur G
MG
Mashru
Rajashree C
RC
D000284:Administration, Oral; D000818:Animals; D002482:Cellulose / Q000031:analogs & derivatives / Q000737:chemistry; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004058:Diffusion; D004337:Drug Carriers; D004339:Drug Compounding; D004355:Drug Stability; D005079:Excipients / Q000737:chemistry*; D005685:Galactans / Q000737:chemistry; D005913:Glipizide / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics*; D065347:Hypromellose Derivatives; D007700:Kinetics; D007785:Lactose / Q000737:chemistry; D008351:Mannans / Q000737:chemistry; D008747:Methylcellulose / Q000031:analogs & derivatives / Q000737:chemistry; D008855:Microscopy, Electron, Scanning; D008954:Models, Biological; D008956:Models, Chemical; D053149:Plant Gums / Q000737:chemistry; D011135:Polysaccharides, Bacterial / Q000737:chemistry*; D011817:Rabbits; D015203:Reproducibility of Results; D012995:Solubility; D013213:Starch / Q000737:chemistry; D013607:Tablets; D013678:Technology, Pharmaceutical / Q000379:methods; D014867:Water / Q000737:chemistry*
D003692:Delayed-Action Preparations; D004337:Drug Carriers; D005079:Excipients; D005685:Galactans; D007004:Hypoglycemic Agents; D008351:Mannans; D053149:Plant Gums; D011135:Polysaccharides, Bacterial; D013607:Tablets; D014867:Water; D065347:Hypromellose Derivatives; C013517:ethyl cellulose; D002482:Cellulose; D008747:Methylcellulose; D013213:Starch; C007894:guar gum; D007785:Lactose; C109691:microcrystalline cellulose; C002563:xanthan gum; D005913:Glipizide